Clinical Trial Update: Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of EUR-1008 (APT-1008) pancreatic enzyme product in cystic fibrosis patients with exocrine pancreatic insuffici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• EUR-1008 (APT-1008) (APT-1008)

Snippet

Sponsor: Forest Laboratories | Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-04-04